17th International Conference of Histochemistry and Cytochemistry, August 27-30, 2025
Vol. 69 No. s2 (2025): 17th ICHC Conference, 2025 | Abstracts

TRACKING HER2 TRAFFICKING AND ORGANELLE CROSSTALK IN TRASTUZUMAB-DERUXTECAN–TREATED BREAST CANCER CELLS USING MULTIMODAL IMAGING

E. Tagliatti1, M. C. Gagliani2, G. Bellese2, M. Crippa3, A. Abbona4, M. Paccagnella4, P. Arnaldi5, M. C. Merlano6, O. Garrone7, A.M. Porcelli8, M. Matteoli1, P. Falletta9, P. Castagnola10, K. Cortese2 | 1IRCCS Humanitas Research Hospital, Laboratory of Pharmacology and Brain Pathology, Rozzano, Milano, Italy; 2DIMES, Department of Experimental Medicine, Cellular Electron Microscopy Lab, University of Genoa, Genoa, Italy; 3Experimental Imaging Center, IRCCS Ospedale San Raffaele, Milan, Italy; 4Health Department S. Croce e Carle Teaching Hospital, Cuneo, Italy; 5IRCCS Ospedale Policlinico San Martino, Genova, Italy; 6Scientific Direction, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy; 7Medical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 8FABIT, Department of Pharmacy and Biotechnology and CIRI, Interdepartmental Centre for Industrial Research ‘Scienze Della Vita e Tecnologie per La Salute’, University of Bologna, Bologna, Italy; 9Vita-Salute San Raffaele University, Milan, Italy; 10IRCCS Ospedale Policlinico San Martino, Genova, Italy

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 21 August 2025
178
Views
0
Downloads

Data Availability Statement

OA

Authors

Trastuzumab-deruxtecan (T-DXd) is a clinically effective antibody–drug conjugate (ADC) for HER2+ and HER2-low breast cancers, yet its intracellular mechanisms remain elusive. We used a multimodal imaging approach including confocal, immuno-EM, and biochemical assays to investigate T-DXd dynamics in HER2+ breast cancer cells. Cells were treated with T-DXd (10 µg/mL, 2– 72 h) and compared to IgG controls. Early-phase responses (2–24 h) included HER2 phosphorylation, sustained ERK signaling despite total ERK reduction, and AKT downregulation. Imaging revealed active lysosomal remodeling, increased TFEB, and reduced LAMP1 and LC3, indicating modulation of autophagic flux. In late stages (48–72 h), T-DXd–HER2 complexes accumulated in lysosomes, forming previously undescribed lysosome–mitochondria–nucleus contact sites. These triads correlated with mitochondrial damage, γH2AX activation, nuclear envelope stress, and LaminB1 increase. Secreted cytokines (IL-6, IL-8, TNF-α) induced M2-like macrophage polarization. This study highlights the value of integrated imaging to dissect the morphofunctional responses induced by ADCs and proposes new cellular targets, such as lysosomal hubs or ERK signaling, for future therapeutic combinations.

Downloads

Download data is not yet available.

Citations

1. Castagnola P, et al. Oncotarget, 2016;7:85411–29 DOI: https://doi.org/10.18632/oncotarget.13392
2. Bellese G, et al. Biochem Pharmacol. 2023;213:115633. DOI: https://doi.org/10.1016/j.bcp.2023.115633
3. D'Alesio C, et al. Biol Open. 2019;8:bio038323.
4. Santamaria S, et al. J Histochem Cytochem. 2021;69:461-73. DOI: https://doi.org/10.1369/00221554211026297
5. Cortese K, et al. Mol Biol Cell. 2013;24:129-44.

Supporting Agencies

-

How to Cite



1.
TRACKING HER2 TRAFFICKING AND ORGANELLE CROSSTALK IN TRASTUZUMAB-DERUXTECAN–TREATED BREAST CANCER CELLS USING MULTIMODAL IMAGING: E. Tagliatti1, M. C. Gagliani2, G. Bellese2, M. Crippa3, A. Abbona4, M. Paccagnella4, P. Arnaldi5, M. C. Merlano6, O. Garrone7, A.M. Porcelli8, M. Matteoli1, P. Falletta9, P. Castagnola10, K. Cortese2 | 1IRCCS Humanitas Research Hospital, Laboratory of Pharmacology and Brain Pathology, Rozzano, Milano, Italy; 2DIMES, Department of Experimental Medicine, Cellular Electron Microscopy Lab, University of Genoa, Genoa, Italy; 3Experimental Imaging Center, IRCCS Ospedale San Raffaele, Milan, Italy; 4Health Department S. Croce e Carle Teaching Hospital, Cuneo, Italy; 5IRCCS Ospedale Policlinico San Martino, Genova, Italy; 6Scientific Direction, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy; 7Medical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 8FABIT, Department of Pharmacy and Biotechnology and CIRI, Interdepartmental Centre for Industrial Research ‘Scienze Della Vita e Tecnologie per La Salute’, University of Bologna, Bologna, Italy; 9Vita-Salute San Raffaele University, Milan, Italy; 10IRCCS Ospedale Policlinico San Martino, Genova, Italy. Eur J Histochem [Internet]. 2025 Aug. 21 [cited 2025 Dec. 28];69(s2). Available from: https://www.ejh.it/ejh/article/view/4305

Share